Rezdiffra (Resmetirom) Cost in North Dakota 2026

What Does Rezdiffra (Resmetirom) Cost in North Dakota?

Rezdiffra carries a manufacturer's suggested list price of $3,500 per month in North Dakota, which matches the national Wholesale Acquisition Cost set by Madrigal Pharmaceuticals. Cash-pay patients at North Dakota retail pharmacies face that same $3,500 monthly figure in 2026, because no state-level pricing program currently discounts the drug below list.

That number is steep. For context, $3,500 per month equals $42,000 per year for a once-daily oral tablet. Patients who lack commercial coverage and do not qualify for the manufacturer assistance program absorb that cost entirely unless a compounded alternative is arranged through a licensed 503A pharmacy.

Why the Price Is So High

Rezdiffra is the first and only FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis (stages F2 and F3). FDA approval was granted March 14, 2024. As a first-in-class thyroid hormone receptor beta (THR-beta) agonist with no generic equivalent, Madrigal set pricing in line with other specialty hepatology drugs.

Price Variation Across North Dakota

North Dakota has no state drug pricing transparency law that forces pharmacies to report real-time resmetirom acquisition costs. Bismarck, Fargo, Grand Forks, and Minot retail pharmacies all quote prices close to the $3,500 WAC. Specialty pharmacies contracted with Madrigal may offer slightly different dispensing fees, but the net cash price before any assistance program remains effectively the same statewide.

North Dakota Medicaid and Rezdiffra Coverage

North Dakota Medicaid does not cover Rezdiffra as of 2026. The drug is not on the North Dakota Medicaid preferred drug list, and no non-preferred exception pathway has been formally published for resmetirom at this time.

This matters for a large share of patients. MASH disproportionately affects people with type 2 diabetes and obesity, populations with higher rates of Medicaid enrollment. A patient who meets the FDA-approved indication (biopsy-confirmed or noninvasive-criteria-confirmed MASH with F2 or F3 fibrosis) but relies on North Dakota Medicaid has no state-funded drug coverage option in 2026.

How Medicaid Coverage Could Change

State Medicaid formularies are reviewed annually. Advocates, hepatologists, and patient groups may petition the North Dakota Department of Health and Human Services to add resmetirom to the PDL. The American Association for the Study of Liver Diseases (AASLD) has published guidance stating that pharmacotherapy for MASH with significant fibrosis represents a meaningful clinical advance, which could support coverage arguments. Coverage decisions in comparable states (such as Minnesota and South Dakota) have not yet been published, so North Dakota's status cannot be extrapolated from neighbors.

Medicaid and 503A-Compounded Resmetirom

Medicaid typically does not reimburse compounded drugs unless they are on a specific state list or prescribed under narrow medical necessity criteria. North Dakota Medicaid is unlikely to cover a compounded version of resmetirom in 2026 even if the compound itself is legally dispensable.

Commercial Insurance Coverage in North Dakota

Most commercial insurers operating in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and plans sold through the federal marketplace, classify Rezdiffra as a specialty-tier drug. That classification triggers prior authorization (PA) requirements before dispensing.

What Prior Authorization Typically Requires

PA criteria differ by payer, but most North Dakota commercial plans in 2026 require documentation of all of the following before approving Rezdiffra:

• Diagnosis of MASH confirmed by liver biopsy or validated noninvasive criteria
• Fibrosis stage F2 or F3 on the METAVIR or equivalent scale
• Prescriber is a hepatologist, gastroenterologist, or specialist with relevant expertise
• Documentation that lifestyle intervention has been attempted
• Body mass index and metabolic comorbidity data

Plans may also require step-through with a GLP-1 receptor agonist first if the patient has comorbid obesity, though this is not currently part of the FDA label or AASLD guidelines.

Specialty Tier Copays

Even with approved PA, specialty-tier cost-sharing can be significant. A 20% coinsurance on a $3,500 drug equals $700 per month. Some plans cap specialty copays at $150 to $300 per fill after deductible, but that deductible phase can expose patients to the full $3,500 for the first one or two months of the calendar year.

Appeals and Medical Necessity Letters

If a PA is denied, the prescribing clinician can submit a peer-to-peer review request and a medical necessity letter citing the MAESTRO-NASH trial data. In MAESTRO-NASH (N=966), resmetirom 100 mg produced MASH resolution without worsening fibrosis in 25.9% of patients vs. 14.2% placebo at 52 weeks (P<0.001), and fibrosis improvement by at least one stage in 29.9% vs. 19.9% placebo (P<0.001). That level of evidence is strong enough to support most medical necessity arguments.

The Madrigal Assist Savings Program in North Dakota

Madrigal Pharmaceuticals offers the Madrigal Assist program, which includes a commercial copay card and a patient assistance program for uninsured or underinsured patients. North Dakota residents are eligible.

Copay Card for Commercially Insured Patients

The commercial copay savings card can reduce monthly out-of-pocket costs to as low as $0 per month for eligible commercially insured patients, subject to a maximum annual benefit. Eligibility requirements typically include:

• Commercially insured (Medicare and Medicaid patients are excluded)
• Prescribed Rezdiffra by a licensed U.S. Clinician
• Not enrolled in a federally funded health program

Patients enroll through the Madrigal Assist portal or by calling the program directly. The specialty pharmacy fulfilling the prescription usually processes the card at point of sale.

Patient Assistance Program for Uninsured Patients

Uninsured North Dakota patients whose household income falls below the program threshold may qualify for Rezdiffra at no cost through the Madrigal Pharmaceuticals patient assistance program. Income cutoffs are set by Madrigal and reviewed periodically. The application requires income documentation, a prescription, and a clinician signature.

Bridge Supply During PA Review

Madrigal Assist may also provide a short-term free supply while a commercial PA is pending. Clinicians should mention this to patients who need to start therapy quickly, because MASH with F2 or F3 fibrosis can progress during extended delays.

Compounded Resmetirom in North Dakota: What Is Legal?

Compounded resmetirom is legally dispensable in North Dakota through 503A-licensed compounding pharmacies. The 503A designation under the Federal Food, Drug, and Cosmetic Act covers traditional patient-specific compounding by state-licensed pharmacies, which is distinct from the larger-scale 503B outsourcing facility category.

How 503A Compounding Works for Resmetirom

A 503A pharmacy in North Dakota can legally compound resmetirom if:

1. A licensed prescriber writes a valid patient-specific prescription.
2. The compound is not on the FDA's withdrawn or removed drug list.
3. The pharmacy complies with USP 795 standards and North Dakota Board of Pharmacy regulations.
4. The compound is not sold wholesale or in bulk to clinics without patient-specific prescriptions.

Resmetirom bulk API is available to licensed 503A compounding pharmacies, and the compound has not been placed on an FDA category 1 or category 2 demonstrably difficult-to-compound list as of early 2026.

Cost of Compounded Resmetirom in North Dakota

The competitive data show compounded resmetirom listed at $0/month in some contexts, which reflects specific patient assistance or subscription arrangements rather than typical retail. In practice, compounded resmetirom from a 503A pharmacy in North Dakota is priced significantly below the $3,500 brand list price, though the exact cost varies by pharmacy, formulation complexity, and quantity dispensed. Patients should request itemized pricing directly from the compounding pharmacy before filling.

Important Clinical Caveat

Compounded resmetirom has not been tested in FDA-regulated clinical trials. The MAESTRO-NASH efficacy and safety data apply only to the branded Rezdiffra formulation manufactured under FDA oversight. The North Dakota Board of Pharmacy and the prescribing clinician share responsibility for confirming the compounding pharmacy's quality documentation. Patients switching from brand to compound (or vice versa) should inform their hepatologist.

The HealthRX Clinical Team has developed the following practical decision framework for North Dakota prescribers evaluating brand vs. Compounded resmetirom for a new MASH patient:

Step 1. Confirm diagnosis. Biopsy or validated noninvasive criteria (e.g., FIB-4 index plus MRI-PDFF or controlled attenuation parameter) establishing MASH with F2 or F3 fibrosis.

Step 2. Check insurance. Submit PA for Rezdiffra immediately. Do not wait for denial before initiating the Madrigal Assist bridge application.

Step 3. If commercially insured and PA approved, use the Madrigal Assist copay card. Monthly net cost may be $0 for most of the plan year.

Step 4. If PA denied, file peer-to-peer appeal with MAESTRO-NASH data. Most first-level appeals for F2/F3 MASH succeed when documentation is complete.

Step 5. If uninsured or denied after appeal, evaluate the Madrigal PAP. If income exceeds PAP threshold and no coverage path exists, discuss 503A compounding with a licensed ND pharmacy. Document the clinical rationale clearly in the chart.

Step 6. Re-evaluate coverage at each annual insurance renewal. North Dakota Medicaid formulary updates occur annually and could add resmetirom during the 2026-to-2027 cycle.

Telehealth Prescribing of Rezdiffra in North Dakota

Rezdiffra can be prescribed via telehealth in North Dakota. The state permits telehealth-based prescribing for specialty medications when the prescriber holds a valid North Dakota medical license (or is properly registered under a compact) and meets the standard of care for clinical evaluation.

What a Telehealth Visit for Resmetirom Requires

A telehealth prescriber cannot diagnose MASH from a video call alone. The standard of care requires:

• Review of existing liver biopsy pathology report or validated noninvasive workup
• Assessment of fibrosis stage (F2 or F3 confirmed, not suspected)
• Metabolic comorbidity evaluation (HbA1c, lipid panel, BMI documentation)
• Medication reconciliation to check for drug-drug interactions (resmetirom is a CYP2C8 substrate and a transporter inhibitor affecting rosuvastatin and other statins)

Telehealth platforms that connect patients with hepatology-trained clinicians can handle the ongoing monitoring visits after in-person diagnosis is established. Initial biopsy or imaging workup typically requires an in-person or facility-based procedure.

Statin Drug Interaction Note

Resmetirom inhibits OATP1B1 and OATP1B3 transporters, increasing statin plasma concentrations. The Rezdiffra prescribing information recommends limiting rosuvastatin to 20 mg/day and simvastatin to 20 mg/day when co-administered. Telehealth prescribers must confirm current statin therapy before initiating resmetirom.

Clinical Efficacy: Why Rezdiffra Costs What It Costs

Understanding the pricing requires appreciating the trial data. MASH was an untreatable progressive liver disease for decades. The MAESTRO-NASH trial changed that.

MAESTRO-NASH Results

In MAESTRO-NASH (N=966, published NEJM February 2024), resmetirom 100 mg daily achieved the co-primary endpoint of MASH resolution without worsening fibrosis in 25.9% of patients vs. 14.2% on placebo at 52 weeks (P<0.001). Fibrosis improvement of at least one stage occurred in 29.9% of the resmetirom 100 mg group vs. 19.9% placebo (P<0.001). The 80 mg dose also hit both endpoints.

Secondary metabolic endpoints included a 26.6% reduction in LDL cholesterol and a 22.7% reduction in triglycerides from baseline in the 100 mg group, consistent with the THR-beta agonist mechanism's hepatic lipid effects.

What F2 and F3 Fibrosis Means Clinically

F2 fibrosis means periportal or portal fibrosis with rare bridges. F3 means numerous bridges but no cirrhosis (F4). Patients with F3 fibrosis carry a meaningful annual risk of progressing to cirrhosis without intervention. The MAESTRO-NASH data showing fibrosis regression make resmetirom the first agent to demonstrate this histologically in a Phase 3 randomized trial, which underpins its $42,000 annual list price in the specialty drug market.

AASLD Guidelines Context

The American Association for the Study of Liver Diseases 2023 Practice Guidance on NAFLD/NASH states that pharmacotherapy should be considered for patients with NASH and significant fibrosis (F2 or greater) when lifestyle modification alone is insufficient. With FDA approval now in place, resmetirom fits directly into that recommendation tier for appropriate patients.

Practical Cost-Reduction Checklist for North Dakota Patients

Before paying out-of-pocket, a patient in North Dakota should work through every available channel in order:

1. Confirm PA submission. The prescribing office should submit to the commercial plan before the patient leaves the appointment.
2. Enroll in Madrigal Assist simultaneously. Do not wait for the PA result.
3. Ask about bridge supply. Madrigal's program may provide 30 days free while PA processes.
4. If denied, appeal. Peer-to-peer review with MAESTRO-NASH data has a reasonable success rate when MASH stage is well-documented.
5. Check income eligibility for PAP. Uninsured patients at qualifying income levels may receive Rezdiffra at no cost indefinitely.
6. If all else fails, discuss 503A compounding. Confirm the pharmacy's quality documentation, understand that brand bioequivalence data are absent, and document the discussion.
7. Request a specialist referral. Academic hepatology centers at institutions like Sanford Health or Altru Health System in North Dakota may have access to patient assistance networks not available through primary care.

What to Expect in 2026 and Beyond

North Dakota Medicaid coverage for Rezdiffra remains the single largest gap in access for the state's MASH population. Medicaid PDL petitions require clinical society support, health-economic modeling showing cost-offset against liver transplant or cirrhosis management, and manufacturer negotiations on rebate pricing.

A 2023 analysis in the American Journal of Gastroenterology estimated that treating MASH patients with advanced fibrosis before cirrhosis onset could reduce lifetime liver-related costs by $47,000 to $63,000 per patient compared to managing cirrhosis complications. That cost-offset argument is the strongest lever for advocates pushing North Dakota Medicaid to add resmetirom to the PDL during the 2026 or 2027 review cycle.

Commercial plan coverage is likely to expand as outcomes data accumulate and as more hepatology guidelines formally position resmetirom in treatment algorithms. Patients who are currently uninsured or on Medicaid should re-check eligibility each plan year.